Summary

Eligibility
for people ages 18-63 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
Principal Investigator
by Namita A Goyal

Description

Summary

Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for participants who completed all scheduled treatments and follow-up assessments in BCT-002-US study

Official Title

Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Details

This is an Intermediate-size patient population Expanded Access Protocol (EAP) to provide NurOwn® (MSC-NTF cells) for eligible ALS participants who completed the BCT-002-US phase 3 ALS clinical trial and have received all three IT treatments. The participants will undergo up to three intrathecal (IT) treatments with NurOwn® (MSC-NTF cells). The first treatment will be at Visit 3, approximately 5-6 weeks after the BMA (Visit 2), with the subsequent treatments at Visit 4 and Visit 5. Following the third and last treatment, the participant will be followed for three additional monthly visits (in-person, if feasible, or by telephone call or telemedicine in consideration of the ongoing COVID-19 pandemic) through week 28, during which the ALSFRS-R and safety assessments will be collected.

Keywords

Amyotrophic Lateral Sclerosis Motor Neuron Disease Sclerosis NurOwn (MSC-NTF cells)

Eligibility

You can join if…

Open to people ages 18-63

  1. Participation in the BCT-002-US study, successful completion of all scheduled treatments and follow-up assessments.

2 Able to provide to the Investigator written informed consent regarding the investigational drug, or, as applicable, on whose behalf a legally authorized representative of the participant has provided such consent.

  1. Able to safely undergo a bone marrow aspiration.

You CAN'T join if...

  1. Inability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate treatment procedures for any other reason (lying flat with BiPAP or NIV are not exclusionary).
  2. History of clinically significant autoimmune disease (excluding thyroid disease) myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis.
  3. Any unstable clinically significant medical condition other than ALS (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the Investigator, would compromise the safety of the participant.
  4. Any history of malignancy within the previous 5 years, with the exception of non-melanoma localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline).
  5. Current use of immunosuppressant medication or use of such medication within 4 weeks of the pre-treatment visit.
  6. Any history of acquired or inherited immune deficiency syndrome.
  7. Tracheostomy and/or mechanical ventilation. Feeding tube use, BiPAP or NIV are not exclusionary.
  8. Pregnant women or women currently breastfeeding or unwilling to use effective birth control methods during the treatment (if of childbearing age).
  9. Positive test result for Hepatitis B virus (HBV; surface antigen (HBsAg) and IgM antibodies to core antigen (IgM anti-HBc)), Hepatitis C virus (HCV), Human Immune deficiency virus (HIV) 1 and 2.

Locations

  • University of California Irvine Alpha Stem Cell Clinic not accepting new patients
    Irvine California 92697 United States
  • Cedars-Sinai Medical Center not accepting new patients
    Los Angeles California 90048 United States

Lead Scientist at UC Irvine

Details

Status
not accepting new patients
Start Date
Sponsor
Brainstorm-Cell Therapeutics
ID
NCT04681118
Study Type
Expanded Access
Last Updated